- Home
- TERN vs SLN Comparison
TERN vs SLN Comparison
Compare TERN & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- SLN
- Stock Information
- Founded
- TERN 2017
- SLN 1994
- Country
- TERN United States
- SLN United Kingdom
- Employees
- TERN N/A
- SLN N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- SLN Health Care
- Exchange
- TERN Nasdaq
- SLN Nasdaq
- Market Cap
- TERN 355.9M
- SLN 352.2M
- IPO Year
- TERN 2021
- SLN N/A
- Fundamental
- Price
- TERN $4.01
- SLN $4.79
- Analyst Decision
- TERN Buy
- SLN Buy
- Analyst Count
- TERN 5
- SLN 4
- Target Price
- TERN $18.30
- SLN $46.25
- AVG Volume (30 Days)
- TERN 1.7M
- SLN 334.1K
- Earning Date
- TERN 03-13-2025
- SLN 02-27-2025
- Dividend Yield
- TERN N/A
- SLN N/A
- EPS Growth
- TERN N/A
- SLN N/A
- EPS
- TERN N/A
- SLN N/A
- Revenue
- TERN N/A
- SLN $21,773,221.00
- Revenue This Year
- TERN N/A
- SLN N/A
- Revenue Next Year
- TERN N/A
- SLN $104.98
- P/E Ratio
- TERN N/A
- SLN N/A
- Revenue Growth
- TERN N/A
- SLN N/A
- 52 Week Low
- TERN $3.96
- SLN $4.06
- 52 Week High
- TERN $11.40
- SLN $27.72
- Technical
- Relative Strength Index (RSI)
- TERN 33.73
- SLN 41.33
- Support Level
- TERN $4.01
- SLN $4.71
- Resistance Level
- TERN $4.24
- SLN $5.16
- Average True Range (ATR)
- TERN 0.21
- SLN 0.47
- MACD
- TERN 0.01
- SLN 0.08
- Stochastic Oscillator
- TERN 5.59
- SLN 32.74
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.